Literature DB >> 15830347

Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy.

Mayank M Agarwal1, Niranjan Khandelwal, Arup K Mandal, Satyawati V Rana, Vivek Gupta, Vaddi Chandra Mohan, Gottapu V M K Kishore.   

Abstract

BACKGROUND: Orchidectomy is an accepted form of androgen-deprivation therapy (ADT) for prostate carcinoma. Osteoporosis is common in elderly individuals and is accelerated by ADT. The authors studied changes in bone mineral density (BMD) after ADT and factors that affected those changes.
METHODS: Fifty patients with prostatic adenocarcinoma who opted to undergo orchidectomy were studied prospectively. All patients completed 6 months of follow-up, and 20 of those patients completed 12 months of follow-up. Patients' age, weight, height, body mass index (BMI), physical activity, addiction (smoking, alcohol), dietary calcium intake, and lactose tolerance status were noted. Lumbar spinal (L1-L3) trabecular BMD was measured with quantitative computed tomography (QCT) at baseline and every 6 months for 1 year and was compared with preoperative values. The effects of various patient characteristics on preoperative BMD and changes in BMD also were analyzed.
RESULTS: The mean +/- standard deviation (SD) age of the patients was 69.5 +/- 8.1 years, BMI was 23.5 +/- 3.9 kg/m2, dietary calcium intake was 1066.1 +/- 443.3 mg per day. Thirty-eight percent of patients were lactose intolerant. Sixty-two percent of patients were in the light weight-bearing activity group. The mean +/- SD preoperative BMD was 119.2 +/- 34.9 mg/cc, with T-scores of - 1.77 +/- 1.22 and Z-scores of 0.43 +/- 1.27. A decrease in BMD during the first 6 months ( approximately 13%) was statistically significant (P = 0.0001) and continued further during next 6 months (BMD loss of approximately 18% at 12 months). Patients with osteoporosis, as defined by T-scores < or = - 2.5, increased from 24% at baseline to 48% at 6 months. Nonsmokers, nonalcoholics, patients with higher physical activity, and patients with a BMI > 25 kg/m2 had statistically significant higher BMD compared with their counterparts (P < 0.05). Body weight < 60 kg and BMI < 25 kg/m2 were significant risk factors for loss of BMD (P < 0.05). Dietary calcium had a discernible but statistically insignificant effect on BMD (P = 0.16). Lactose intolerance had no significant effect on BMD or bone loss.
CONCLUSIONS: Osteoporosis was common in the population affected by prostate carcinoma. Orchidectomy led to accelerated bone loss. Periodic measurement of BMD after ADT would help in the early detection of osteoporosis. Maintenance of high BMI, weight-bearing physical activity, avoidance of alcohol and smoking, and possibly high dietary calcium intake help in maintaining bone mass.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830347     DOI: 10.1002/cncr.21047

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

Authors:  C E Lee; W D Leslie; P Czaykowski; J Gingerich; M Geirnaert; Y K J Lau
Journal:  Curr Oncol       Date:  2011-08       Impact factor: 3.677

Review 2.  Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies.

Authors:  Myrto Boukovala; Nicholas Spetsieris; Eleni Efstathiou
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

3.  The Exercising Together project: design and recruitment for a randomized, controlled trial to determine the benefits of partnered strength training for couples coping with prostate cancer.

Authors:  Kerri M Winters-Stone; Karen S Lyons; Lillian M Nail; Tomasz M Beer
Journal:  Contemp Clin Trials       Date:  2011-11-11       Impact factor: 2.226

4.  Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids.

Authors:  B García-Fontana; S Morales-Santana; M Varsavsky; A García-Martín; J A García-Salcedo; R Reyes-García; M Muñoz-Torres
Journal:  Osteoporos Int       Date:  2013-08-01       Impact factor: 4.507

Review 5.  A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma.

Authors:  Ary Serpa Neto; Marcos Tobias-Machado; Marcos A P Esteves; Marília D Senra; Marcelo L Wroclawski; Fernando L A Fonseca; Rodolfo B dos Reis; Antônio C L Pompeo; Auro Del Giglio
Journal:  BMC Urol       Date:  2010-05-19       Impact factor: 2.264

6.  Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases.

Authors:  Feng Wang; Wei Chen; Hongde Chen; Licai Mo; Haiyong Jin; Zhixian Yu; Chengdi Li; Qing Liu; Feifei Duan; Zhiliang Weng
Journal:  Med Oncol       Date:  2013-07-18       Impact factor: 3.064

Review 7.  Cancer Treatment and Bone Health.

Authors:  Catherine Handforth; Stella D'Oronzo; Robert Coleman; Janet Brown
Journal:  Calcif Tissue Int       Date:  2018-01-20       Impact factor: 4.333

Review 8.  Management of cancer treatment-induced bone loss.

Authors:  Robert E Coleman; Emma Rathbone; Janet E Brown
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

9.  Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines?

Authors:  Manas R Pradhan; Anil Mandhani; Saurabh S Chipde; Alok Srivastava; Manmeet Singh; Rakesh Kapoor
Journal:  Indian J Urol       Date:  2012-10

Review 10.  Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.

Authors:  Tae Jin Kim; Kyo Chul Koo
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.